A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia

NCT07017725 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Immune Thrombocytopenia

Interventions

DRUG: CID-103

Sponsor

CASI pharmaceuticals, Inc.